Wow North, great finding of CVS formulary exclusive to brand V, and great deduction of eventual FDA action against the fraudulent Hikma losing the business and hence the disappearance of generic V in the business of the rest of the generics as well. We should eventually see the share price goes to $520 which was the pre R/S high of $26 if I remember correct. Thanks for your continued presence here North, You are great!
North, Yes. The court can make a determination about the legality of FDA actions. They can declare a label unlawful. My point was that they don't have the authority to alter a label. Sleven,
Market Data 
Markets 
AI
